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ABSTRACT 
Objective: The oral bioavailability of Candesartan cilexetil is less (<15%), so in this study an approach has been made to increase its bioavailability 
by proniosomal gel formulation. 
Methods: The proniosomal formulation of Candesartan cilexetil was prepared by slurry method, using span 60 and Tween 60 as non-ionic 
surfactants, maltodextrin as carrier and cholesterol and soya lecithin as stabilizers. Prepared gel formulations were evaluated for compatibility 
study, entrapment efficiency, vesicle size, surface morphology, in-vitro diffusion studies, in-vitro skin permeation studies, in-vivo pharmacokinetics 
studies, various release kinetic studies and stability studies.  
Results: FT-IR study showed no interaction between drugs and other excipients, drugs and excipients are compatible. Mean vesicles size of 
proniosome derived niosome was found in the range of 16.34 µm-32.48 µm and 7.25-16.45 µm before and after shaking. An optimized formulation 
A3 containing a 2:1 ratio of span 60 and cholesterol showed maximum entrapment (86.17%) and in-vitro drug release (93.8%) compared to other 
formulations. In-vitro skin permeation studies were carried out using Albino rat skin and results showed that formulation A3 exhibited 88.65% drug 
permeation in a steady-state manner over a period of 24 h with a flux value of 1.94 µg/cm2/h and enhancement ratio of 3.73. In-vivo 
pharmacokinetics studies of proniosomal gel formulation A3 showed a significant increase in bioavailability (1.425 folds) compared with an oral 
formulation of Candesartan cilexetil. Stability studies showed that proniosomal gel formulation was stable throughout its study period.  
Conclusion: Physiochemically stable Candesartan cilexetil proniosomal gel was formulated, which could deliver significant amount of the drug 
across the skin in a steady-state manner for the prolong period of time in the treatment of hypertension. 
Keywords: Bioavailability, Candesartan cilexetil, proniosomal gel, In-vitro diffusion studies, Entrapment efficiency, Span 60, Tween 60. 
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INTRODUCTION 
In recent years, many drug molecules have been discovered in the 
pharmaceutical field. Most of the new drug candidates used is 
sparingly soluble or poorly soluble and these are associated with 
poor bioavailability. To improve their solubility and bioavailability 
various formulation strategies was made; these include the use of 
surfactants, complexation, nanoparticles, solid dispersions, 
micronization and self-emulsifying drug delivery systems. Most of 
these approaches have shown limited success because of the need of 
a longer processing time, costly investments as well as complicated 
manufacturing process [1, 2].  
In recent years, vesicular based drug delivery system such as 
liposomes and niosomes is developed in order to improve 
bioavailability of hydrophilic as well as lipophilic drug. These 
vesicular systems are promising systems for transdermal drug 
delivery as they act as vehicles or as permeation enhancers for 
drugs. They also possess greater advantage for a poor soluble drug 
by increasing solubility, controlling the release and prolonging drug 
activity over long periods of time. Inspite of having good chemical 
stability these systems are suffering from various physical stability 
problems such as aggregation, fusion, leakage or hydrolysis of 
encapsulated drugs.  
In order to overcome these drawbacks, the researchers gave focus 
on the development of dry products. Such dry product is called as 
proniosomes ‘‘dry niosomes’’ and they are hydrated immediately 
before use, thus avoids such problems [3, 4]. 
Candesartan cilexetil is an esterified prodrug of Candesartan, a 
potent, long-acting and selective angiotensin (II) type-1 receptor 
antagonist used in the treatment of hypertension and congestive 
heart failure [5]. Candesartan cilexetil is white to off-white 
crystalline powder having melting point of 157-165 °C and is water 
insoluble. It is highly bound to plasma proteins (>99%) and does not 
penetrate red blood cells. It is available in 4 mg, 8 mg, 16 mg and32 
mg. It can be used in the dose range of 8-32 mg/day [6]. 
The main drawback of this medication as an oral dosage form is its poor 
aqueous solubility and low oral bioavailability i.e.<15%. In the present 
study, an attempt was made to enhance the solubility and bioavailability 
of Candesartan cilexetil by transdermal proniosomal gel formulation. 
MATERIALS AND METHODS 
Material and reagents used 
Candesartan cilexetil was procured from Yarrow chem products, 
Mumbai, India. Cholesterol, span 60, maltodextrin, soya lecithin 
were procured from S. D. Fine Chem. Ltd, Mumbai, India. All other 
reagents used were analytical grade. 
Animal used  
Male albino rats weighing 180-220 g were used for skin permeation 
and in-vivo pharmacokinetics studied.  
Ethical approval  
The study protocol was approved by the Institutional Animal Ethics 
Committee (IAEC), Sri Adichunchanagiri College of Pharmacy, B. G. 
Nagara-571448, Karnataka, India. Reg. No. SACCP/IAEC/271(b)/2014-15. 
Compatibility studies FT-IR spectrophotometer (Bruker IR system) 
was used for infra-red analysis of samples to interpret the interactions 
of drug with other excipients. Preparation of proniosomal gel 
Proniosomal gel formulation of candesartan cilexetil was prepared by 
slurry method. Altogether nine formulations were prepared by using 
different drug to carrier ratio. The prepared formulations were 
dissolved in methanol: chloroform (2:1) solution and sonicate for 
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about 10 min. The solution was then added to a 100 ml round bottom 
flask containing the accurately weighed maltodextrin. The flask 
containing physical mixture of drug and carrier was attached to a 
rotary flask evaporator to evaporate solvent at 60 to 70 rpm. The 
temperature and pressure were maintained 45 ˚C and 600 mm of 
Hg respectively until the mass in the flask had become a dry as 
well as free flowing product. This dry powder was referred as 
proniosomes and stored in a tightly closed container in the 
refrigerator at 4˚C temperature [7]. Proniosomes were 
transformed into niosome by hydrating with phosphate buffer (pH 
6.8) at 80 ˚C using vortex mixture for 2-3 min. The niosome was 
sonicated twice for 30 s using sonicator. Then these proniosome-
derived niosome were used to prepare niosomal gel. For this 
purpose equivalent amount of niosomal suspension containing 1 g 
drug was centrifuged and the pellets obtained were mixed with 
1% w/v carbopol 934 dispersion and made it viscous using 
sufficient quantity triethanolamine solution. Formulation design of 
Candesartan cilexetil proniosomal gel is tabulated in table no.1. 
This prepared niosome gel was subjected to various evaluation 
studies [8]. 
  
Table 1: Composition design of candesartan cilexetil proniosomal gel 
S. No. Ingredients Formulation code 
A1 A2 A3 A4 A5 A6 A7 A8 A9 
1.  Candesartan cilexetil (mg) 16 16 16 16 16 16 16 16 16 
2.  Maltodextrin (mg) 500 500 500 500 500 500 500 500 500 
3.  Span 60 (mg) 100 150 200 100 100 100 - - - 
4.  Tween 60 (mg) - - - - - - 100 150 200 
5.  Cholesterol (mg) 100 100 100 150 200 250 100 100 100 
6.  Soya lecithin  100 100 100 100 100 100 100 100 100 
7.  Carbopol 934 (%) 1 1 1 1 1 1 1 1 1 
A1, A2, A3, A4, A5, A6, A7, A8, A9= formulation code of proniosomal gel. 
 
Evaluation of proniosomal gel 
pH determination  
pH of prepared gel was determined by using calibrated pH meter [9]. 
Viscosity and rheological studies 
Brookfield digital viscometer (Model LVDV–E, USA) was used for the 
determination of viscosity and rheological properties of gel [10].  
Drug content analysis 
Proniosomes equivalent to 50 mg were taken into a standard volume 
flask. They were lysed with 25 ml of medium for 15 min. The clear 
solution was diluted to 100 ml of medium. Then 10 ml of this 
solution was diluted to 100 ml of phosphate buffer at pH 6.5. 
Aliquots were withdrawn and the absorbance was measured at 257 
nm and drug content was calculated from the calibration curve [10]. 
Vesicle size analysis  
Size and size distribution studies were done for niosomes obtained 
after hydration of proniosomal gel with agitation and without 
agitation. After hydration, the niosomal dispersion was observed 
under an optical microscope with a calibrated eyepiece micrometer 
which is calibrated with a stage micrometer at 40x magnification [9]. 
Entrapment efficiency 
To determine loading capacity of proniosomal gels, 20 mg of 
Candesartan cilexetil proniosomal gel was weighed and dispersed in 
phosphate buffer of pH 6.5 and warmed a little for the formation of 
niosomes. Free Candesartan cilexetil was separated from 
Candesartan cilexetil loaded niosomes by centrifugation at a speed 
of 14000 rpm for 45 min at 4 oC. The amount of free drug in the 
supernatant was determined at 257 nm using UV 
spectrophotometer. The entrapment efficiency (EE) of Candesartan 
cilexetil was calculated by using following equation [11]. 
The entrapment efficiency was calculated by using following equation:  
EE (%) = [(Ct-Cf)/Ct] ×100 
Where, Ct = total drug and Cf = free drug. 
Vesicular morphology 
Shape and surface morphology of optimized formulation was carried 
out by scanning electron microscopy and photomicrography [9, 11]. 
In-vitro release studies and in-vitro skin permeation studies  
In-vitro release studies and in-vitro skin permeation studies of 
proniosomal gel were carried out for 24 h using pre-soaked 
cellophane membrane and Albino rat skin respectively. Both act as a 
receptor compartment. The proniosomal gel equivalent to 16 mg of 
drug was placed in a glass tube containing membrane. The glass tube 
was placed in a beaker containing 350 ml of phosphate buffer of pH 
6.5 containing 0.35% tween 20 which acts as the receptor 
compartment (37±1ºC). At appropriate time intervals aliquots of 1 
ml sample were withdrawn periodically and after each withdrawal 
same volume of medium was replaced. The collected samples were 
analysed at 257 nm [12, 13]. 
Selection of optimised formulation 
After subjecting all formulations to permeation studies, data of 
cumulative amount of drug permeated through the skin (mg/cm2) 
plotted as a function of time (t). Drug flux at steady state (Jss) was 
calculated by dividing the slope of the graph linear portion with the 
diffusion cell area (mg/cm2/h). Permeability coefficient (Kp) was 
calculated by dividing drug flux at steady state (Jss) with the initial 
concentration of drug in the donor compartment (cm/h) [13, 14]. 
In-vivo bioavability studies  
For in-vivo bioavability studies, twelve Albino rats were taken. Rats 
were divided into two groups (Group A and Group B) each carrying 
six rats. Group A was subjected to transdermal treatment with 
optimized proniosomal gel formulation. The rat abdominal hair was 
carefully shaved by a razor without any skin damage and wash with 
distilled water. The proniosomal gel was applied to the rat skin with 
the entire surface in intimate contact with the stratum corneum. In 
order to keep the gel secured at the site of application, the 
microporous adhesive tape was rolled over the gel. Group B was 
administered with marketed Candesartan cilexetil tablet.  
The dose was calculated based on the body weight of the rats as per the 
surface area ratio method. The rats were anesthetized using ether. Then 
the blood samples (0.5 ml) were withdrawn from the tail vein of rats at 
0.5, 1, 2, 3, 4, 6, 8, 12, 18 and 24 h in micro-centrifuge tubes containing 
the anti-coagulant (sodium citrate buffer). The blood sample was then 
centrifuge at 4500 rpm for 5 min in order to obtain plasma and store 
plasma at-20 °C before analysis. The plasma samples were deproteinised 
by using acetonitrile, again centrifuge and supernatant liquid was 
separated and finally analysed using UV spectrophotometer at 257 nm. 
From the results obtained various pharmacokinetics parameters such as 
Cmax, Tmax, AUC0-t, were calculated. Cmax and Tmax were directly obtained 
from the graph. KE and AUC were calculated by using the residual 
method and trapezoidal method respectively [13, 15]. 
Drug release kinetics 
An investigation of the drug release from gel was done by studying 
the release data with zero order, first order kinetics and Higuchi 
equation. The release mechanism was understood by fitting the data 
to Korsmeyer Peppas model [16].  
Acharya et al. 




The optimized formulation was subjected to three month stability 
studies at 25ºC/60% and 40ºC/75% RH [17]. 
RESULTS AND DISCUSSION 
Compatibility studies using FT-IR 
All the characteristic peaks of Candesartan cilexetil were present in the 
spectrum of drug polymer mixture, indicating compatibility between 
drug and polymer. The spectrum confirmed that there is no significant 
change in the chemical integrity of the drug. There is no change in 
functional group peaks (-C-H, C-N, N-H, C-O-C, C=O) of Candesartan 
cilexetil in all the IR-spectra and is shown in table 2 and fig. 1, 2 and 3. 
pH determination 
pH values of prepared proniosomal gel were found in the range of 
6.7-7.3, which is physiologically acceptable range for topical 
preparations (table 3). 
 
 
Fig. 1: IR Spectrum of pure drug candesartan cilexetil 
 
 
Fig. 2: IR Spectrum of pure drug and its physical mixtures 
 
 
Fig. 3: IR Spectrum of candesartan cilexetil proniosomal gel 
 
Table 2: Interpretations of IR-spectrum pure drug, physical mixtures and gel formulation 
Functional group Wave number (cm-1) 
 Pure drug Drug+physical mixtures Gel formulation 
Aromatic-C-H (s)  2940.2 2919.40 2927.78 
Aromatic-C-H (b) 747.13 677.35 928.18 
C-N (s) 1116.3 1166.99 1080.07 
N-H (s) 3613.7 3615.21 3737.73 
C=O (s) 1752.6 1752.10 1642.86 
C-O-C 1240.4 1235.36 1276.31 
 
Viscosity and rheological studies  
Viscosity of all formulations decreases with an increase in share rate, 
indicating pseudo plastic flow and follow non-Newtonian flow. For 
the topical application, the consistency of the sample is important 
feature, due to the fact that it must be applied to skin in the thin 
layer. For this reason, it is preferable to formulate non-Newtonian 
formulations because of their low resistance to flow when they are 
applied under the high shear rate.  Results were tabulated in table 3 
and fig. 4. 
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Fig. 4: Rheological profile of candesartan cilexetil proniosomal 
gel formulation (A1, A2, A3, A4, A5, A6, A7, A8, A9) 
 
Drug content estimation 
Drug content of all proniosomal gel formulation was found between 
94.65% to 98.42% w/w and a result complies with pharmacopoeial 
limits (table 3). 
Vesicle size analysis 
Vesicle size of Candesartan cilexetil was found in the range of 7.25 
µm to 16.45 µm. The results obtained from vesicle size analysis 
showed that the formulations (A1, A2, A3, A4, A5, A6) containing span 
60 as non-ionic surfactant were smaller in size than vesicles formed 
with tween 60 (A7, A8, A9). Larger size vesicles formed from tween 
60 might be due to lower hydrophobic nature of tween 60. The 
relationship observed between niosome size and span 
hydrophobicity has been attributed to the decrease in surface 
energy with increasing hydrophobicity, resulting in the vesicles with 
small size. Formulations F6 containing high concentration of 
cholesterol also slightly reduced the vesicle size of niosomes which 
might be due to increasing in the hydrophobicity attributed by 
cholesterol. The vesicle size of niosome was larger when the 
dispersion was not agitated but, after agitation the size of vesicle 
was reduced due to breakage of larger vesicles to smaller vesicles. 
Entrapment efficiency (EE) 
Entrapment efficiency of proniosomes formulations ranged from 
62.70% to 86.17%. Niosomes formed from span 60 proniosomal gels 
exhibits higher EE than proniosomal gels prepared from tween 60 
because Span 60 is solid at room temperature and have the highest 
phase transition. Span 60 is having the same head group with 
different alkyl chains. An ability to entrap drug is higher in span 60 
which might be due to presence of longer saturated alkyl chain. A 
larger alkyl chain present in span 60 might lower the HLB value of 
span 60 and thus increases the EE of the drug. Formulation A3 
containing span 60: cholesterol in 2:1 ratio showed highest EE 
(86.17%). As the cholesterol content of the formulation was 
increased, the EE of the drug was also increased. The use of 
cholesterol in the proniosomal formulations not only improves the 
fluidity but also improves the stability of the bilayer membrane 
because EE of niosome is governed by the ability of formulation to 
retain drug molecules in the bilayer membrane of the vesicles. This 
characteristic of cholesterol decreases leakage of the drug molecule 
from the bilayer structure and also provides spherical smooth 
surface to the bilayer vesicles. However, further increase in 
cholesterol level lowers the drug EE of bilayer vesicles formulation 
(A5, A6). This could be due to the fact that the cholesterol beyond a 
certain level starts disrupting the regular bilayer structure of 
vesicles leading to loss of drug entrapment. 
Vesicle morphology 
Scanning electron microscopy (SEM) and photomicrography 
SEM and photomicrography of Candesartan cilexetil proniosomal 
gel formulation A3 revealed that proniosomal vesicles are in 
smaller diameter and spherical shape with a uniform surface. It is 
believed that vesicles with smaller diameter and spherical shape 
can be better diffuse through the skin as smaller vesicles tend to 
fuse readily. The photographs revealed that the niosomes are 
spherical in shape and no aggregation or agglomeration was 
observed. 
 
Table 3: Results of pH, drug content, % entrapment and vesicle size of proniosomal gel 
Parameters A1 A2 A3 A4 A5 A6 A7 A8 A9 Control 
pH* 6.8 7.0 6.7 7.1 7.2 6.8 7.0 7.1 7.3 7.1 
 Drug content (%)* 96.7 95.65 98.42 96.1 95.1 97.30 94.65 97.9 98.1 97.65 
PercentEntrapment* 76.8 83.74 86.8 82.7 75.49 74.92 62.7 66.9 68.4 -- 
Vesicle size (µm)* 10.2 10.18 9.76 9.41 8.67 7.25 16.4 14.7 13.5 -- 
*n =3, Average of three determinations for pH, drug content, percentage entrapment and vesicle size. µm denoted in micrometer. 
 
 
Fig. 5: SEM images of an optimized formulation A3 
 
 
Fig. 6: Photomicrography images of an optimized formulation A3 
 
Fig. 7: In-vitro drug release profile of the candesartan cilexetil 
proniosomal gel formulation (A1, A2, A3, A4, A5, A6, A7, A8, A9) 
 
In-vitro drug release studies 
In this present study in-vitro release profile of Candesartan cilexetil 
proniosomal gel was compared with control gel of Candesartan 
cilexetil (normal gel). The in-vitro diffusion release profile of 
Candesartan cilexetil from proniosomes of different cholesterol 
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contents was apparently biphasic release process. In the first 6 h of 
release studies, rapid release of drug (about 31.42% to 54.66%) was 
observed from almost all formulations which might be due to the 
initial bursting of improper niosomes in the formulations (fig. 6). 
However, in between 6 h to 24 h, most of the formulation showed 
57.62% to 93.81% of drug release. In case of control gel release rate 
was found relatively low i.e. 49.04% after 24 h. higher release rate of 
proniosomal gel compared to control gel might be due to 
penetration enhancement effect of non-ionic surfactants. The 
amount of drug released from different batches of proniosomal gel 
formulations was in the order of A3>A4>A2>A1>A6>A5>A9> 
A8>A7>control.  
In-vitro skin permeation studies 
In-vitro skin permeation studies were performed for Candesartan 
cilexetil normal gel and proniosomal gel using rat skin. From this 
study the cumulative amount of Candesartan cilexetil permeated per 
unit area across excised rat skin as the function of time, flux, 
permeability coefficient and enhancement ratio Er, was determined. 
The results of permeation studies showed that formulations 
containing non-ionic surfactants (Tween 60 and span 60) exhibited 
higher percentage of drug permeation compared to control 
formulation (46.98%) after 24 h (fig. no. 8). Candesartan cilexetil 
proniosomal gel showed higher permeation because non-ionic 
surfactant present in these formulation acts as permeation 
enhancers. Among nine formulations, formulation containing span 
60 showed higher skin permeation compared to formulation 
containing tween 60. Lower skin permeation of formulation 
containing tween 60 might be due to the larger size of the vesicles 
and less lipophilic nature of the tween, which makes more difficult 
for these vesicles to penetrate through the skin. Among all the 
formulations, formulation A3 containing surfactant and cholesterol in 
a 2:1 ratio showed higher percentage of drug permeation 85.65%. 
Formulation A3 showed better entrapment with optimum vesicle 
size, which leads to better permeation through the skin. All 
permeability parameters such as flux (Jss), permeability coefficient 
(Pb), and enhancement ratio (Er) were found to be higher for 
formulation A3 (table 4) compared with other formulation. All the 
proniosomal gel preparations, A1 to A9 provided absorption of the 
drug through the Albino rat skin up to 24 h in a sustain manner. The 
mechanism of proniosomes derived niosomes to transfer the drug 
across the skin could be penetration enhancer effect of non-ionic 
surfactants. These non-ionic surfactants acts by loosening the 
intercellular lipid barrier of the stratum corneum resulted in higher 
flux of the drug. Higher the flux value, larger the drug transfers 
directly from vesicles to the skin.  
 
 
Fig. 8: In-vitro drug permeation studies of proniosomal gel 
formulation (A1, A2, A3, A4, A5, A6, A7, A8, A9, control) 
 
 
Fig. 8: In-vitro drug permeation studies of proniosomal gel 
formulation (A1, A2, A3, A4, A5, A6, A7, A8, A9, control)
 
Table 4: Permeability parameters of different proniosomal gel formulation (A1, A2, A3, A4, A5, A6, A7, A8, A9 and control gel) 
Formulation code Flux value (J) (µg/cm2/h) Permeability coefficient (Kp) (cm/h) Enhancement ratio (Er) 
A1 1.66 0.0835 3.277 
A2 1.81 0.0910 3.50 
A3 1.93 0.0970 3.73 
A4 1.85 0.0925 3.55 
A5 1.07 0.0535 2.05 
A6 1.23 0.0615 2.36 
A7 0.69 0.0345 1.32 
A8 0.73 0.0364 1.40 
A9 0.98 0.0495 1.88 
Control 0.52 0.0225 - 
 
In-vivo pharmacokinetics studies 
Based on the results of permeability parameters formulation A3 was 
selected for pharmacokinetics studies. Pharmacokinetics studies were 
carried out on Albino rats to evaluate the efficacy and bioavailability of 
the developed transdermal gel formulation against the oral dosage 
form. Cmax and Tmax were directly read from the graph (fig. no. 9). 
The mean Tmax of Candesartan cilexetil was 4 h for oral route and 6 h 
for transdermal route. Higher Tmax value of transdermal treatment 
compared to oral treatment indicated the control drug release 
behaviour of the transdermal gel formulation. The mean Cmax value of 
Candesartan cilexetil was 170.42 ng/ml for oral treatment and 164.8 
ng/ml for transdermal. The Cmax values for both routes were almost 
similar, but graph showed that in the case of oral route the peak and 
valley pattern was quite evident with the fluctuation in the plasma 
drug concentration whereas in the case of transdermal route steady-
state plasma concentration level was maintained throughout 24 h. The 
relative bioavailability of Candesartan cilexetil after transdermal 
application was found to be 1.425 times higher than that of oral 
delivery. The increase in bioavailability of transdermal delivery might 
be due to elimination of hepatic first pass metabolism by this route. In 
addition, transdermal gel provides much steadier plasma 
concentration-time curve compared to oral tablet in 24 h periods of 
treatment. Thus, a stable anti-hypertensive effect of Candesartan 
cilexetil could be obtained for longer period of time after its 
transdermal proniosomal gel application. 
 
Table 5: Pharmacokinetics parameters of Candesartan cilexetil after its transdermal and oral administration 
Formulation Tmax (h) Cmax (ng/ml) AUC0-t (ng. h/ml) KE (h-1) t1/2 (h) Relative bioavailability 
A3* 6 164.8 1824.03 0.0852 8.133 1.425 
Marketed tablet* 4 170.42 1298.42 0.0741 9.35 - 
*= n, Average of three determination for each parameters 
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Fig. 9: Serum concentration of candesartan cilexetil in rat 
serum after transdermal and oral application 
 
Drug release kinetics 
The cumulative release data were subjected to various kinetics 
models and results obtained from release kinetics studies were 
depicted in table no. 6. The in-vitro release profile of drug from all 
gel formulations could be expressed by Higuchi’s equation, as the 
plots shows high linearity (R2 = 0.8954-0.980) in comparison to zero 
order (R2= 0.710-0.90) and first order (R2= 0.8020-0.959). So, it was 
understood that Higuchi’s release pattern was followed by all 
formulations. To confirm diffusion mechanism the data were fitted 
into Korsmeyer-Peppas model.  
All gel formulations A1 to A9 showed high linearity (R2 = 0.5936-
0.685) with slope (n) ranging from 0.8231 to 0.905, indicating that 
the drug was released from proniosomal gel by diffusion-controlled 
mechanism. For the formulations (A1, A2, A3, A7, A8 and A9), the 
values for ‘n’ ranged 0.45<n = 0.89 which indicates that all these 
formulations followed Non-Fickian release mechanism and 
remaining formulations (A4, A5 and A6) followed Super case II 
transport mechanism as their ‘n’ values are higher than 0.89. 
Stability studies 
Stability studies were carried out at 25ºC/60% and 40ºC/75% RH 
for a period of 3 mo. Optimized gel formulations A3 and A4 were 
selected for stability studies in order to study the effect temperature 
and humidity on gel formulations. The gel formulation A3 and A4 
were analysed for visual appearance, pH, viscosity, vesicle size, % 
entrapment efficiency, drug content and in-vitro release studies.  
First month of stability studies revealed that there was no change in the 
physiochemical characteristics of both gel formulations. In between 2 to 
3 mo both the formulation has shown slight changes in pH and viscosity 
which was in acceptable limits (±0.5). No significant changes were 
observed in proniosomal gel formulation during study period. Thus it 
can be concluded that both the formulations were stable. 
  
Table 6: Release exponent values and rate constant values for different formulation (A1, A2, A3, A4, A5, A6, A7, A8, A9) 
Formulation code Kinetics models Best fit model Drug release mechanism 
Zero order First order Higuchi Korsmeyer-peppas 
R2 R2 R2 R2 N 
A1 0.7873 0.8987 0.9441 0.648 0.8845 Higuchi non-Fickian  
A2 0.7158 0.8026 0.8954 0.6187 0.8820 Higuchi non-Fickian 
A3 0.8035 0.9595 0.9623 0.5936 0.8743 Higuchi non-Fickian 
A4 0.8580 0.9105 0.9637 0.6560 0.9052 Higuchi Super case II 
A5 0.7799 0.8856 0.9397 0.6371 0.8977 Higuchi Super case II  
A6 0.7474 0.8347 0.9142  0.6627 0.9308 Higuchi Super case II 
A7 0.9053 0.9594 0.9800 0.6853 0.8231 Higuchi non-Fickian 
A8 0.8251 0.8993 0.9673 0.6712 0.8606 Higuchi non-Fickian 
A9 0.8158 0.9003 0.9689 0.6033 0.8091 Higuchi non-Fickian 
 
CONCLUSION  
In this present study, an attempt has been made to increase the 
bioavailability of Candesartan cilexetil by proniosomal gel formulation. 
From the experimental results, it can conclude that, physiochemically 
stable proniosomal gel was formulated and gel formulation showed 
1.425 times increase in bioavailability compared to an oral dose of 
Candesartan cilexetil. This type formulation can deliver drug in sustain 
manner for the prolong period of time in the treatment of hypertension 
with better patient compliances and convenience.  
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